Dexcom To Expand CGM Manufacturing To Greater Phoenix, AZ

New State of the Art Manufacturing Facility will Help Meet Growing Demand for Continuous Glucose Monitoring Technology

SAN DIEGO -- Dexcom, Inc. (NASDAQ: DXCM), a leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that it will construct a new state of the art manufacturing facility in Greater Phoenix, Arizona for the company's growing continuous glucose monitoring (CGM) business. This new, 180,000 square foot facility will support the company's global manufacturing operations and is projected to create more than 500 jobs over the next several years. We expect initial manufacturing operations in this facility to commence in the second quarter of 2017.

"We are thrilled to locate our new state of the art manufacturing facility in the greater Phoenix area where the healthcare industry is seeing accelerated growth," said Kevin Sayer, President and Chief Executive Officer of Dexcom. "We chose Mesa due to the available, talented workforce, in addition to the proximity to our headquarters in San Diego and our key suppliers. Given our company's growth, and the growing demand for CGM technology, we felt that a significant expansion of our manufacturing capability in this location was a good strategic fit."

Diabetes affects 29.1 million Americans and is the 7th leading cause of death in the United States.[i]  With diabetes, the body cannot produce or use the hormone insulin effectively, causing a buildup of glucose, or sugar, in the blood. Obesity, physical inactivity and poor diet are risk factors for the development of diabetes.[ii] People with diabetes who take insulin must monitor their blood glucose levels frequently. Uncontrolled glucose can cause health complications and even death.[iii],[iv]

Advances in technology have helped those with diabetes stay on top of their glucose levels. Continuous glucose monitoring is considered the most significant breakthrough in diabetes management in the past 40 years.[v] With the recent introduction of the Dexcom G5 Mobile CGM System, people with diabetes can now view their glucose information on their iOS-enabled devices for real-time diabetes management. CGM is important because, in addition to providing the glucose level, it provides the direction and rate of glucose change with the push of a button and alerts users when glucose is too low or too high.

About Dexcom, Inc. 
Dexcom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric patients.  With exceptional performance, patient comfort and lifestyle flexibility at the heart of its technology, users have consistently ranked Dexcom highest in customer satisfaction and loyalty. For more information on the Dexcom CGM, visit www.dexcom.com.

____________________________________________

[i] 2014 National Diabetes Statistics Report. Centers for Disease Control and Prevention.http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf  Accessed March 31, 2015.
[ii] Data and Statistics, World Health Organization Web site, Available at: http://www.euro.who.int/en/health-topics/noncommunicable-diseases/diabetes/data-and-statistics
[iii] Hyperglycemia (High blood glucose). American Diabetes Association Web site. http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hyperglycemia.html.  Updated August 5, 2013. Accessed December 3, 2013.
[iv] Hypoglycemia (Low blood glucose). American Diabetes Association Web site. http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hypoglycemia-low-blood.html.  Updated July 16, 2013. AccessedDecember 3, 2013.
[v] Clarke SF and Foster JR. A history of blood glucose meters and their role in self-monitoring of diabetes mellitus. Br J Biomed Sci. 2012;(3)2:83-93.